Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

migraine

This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

Botox is normally offered to patients when at least three oral preventative treatments have been tried for those with chronic migraine. ... Ahmad confirmed that the company would continue to work with NICE to secure access for those with chronic migraines

Latest news

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    There were also a number of drugs with brand new mechanisms of action, including three CGRP inhibitors for migraine prevention from Amgen, Teva and Eli Lilly – as well as Agios

  • Amgen CEO says Aimovig is “one of most successful launches” Amgen CEO says Aimovig is “one of most successful launches”

    Bob Bradway. “People suffering from migraine and their physicians have been waiting for years for an effective new therapy and they've reacted very well to Aimovig,” he said. ... There’s no doubt that the rapid roll-out comes from pent-up demand

  • Teva wins FDA OK for crucial migraine drug Teva wins FDA OK for crucial migraine drug

    Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig. Teva has secured US approval for migraine drug Ajovy, a key part of new chief execeutive Kåre Schultz's ... The FDA approved the CGRP inhibitor for the prevention of migraine in

  • US insurers can peg access to ICER value reviews US insurers can peg access to ICER value reviews

    It also recommends when prior authorization should be obtained – for example with the new CGRP inhibitor migraine drugs.

  • First migraine prevention drug to hit European market First migraine prevention drug to hit European market

    It was reported that those on Aimovig also experienced significant reductions in their number of migraine days per month. ... In clinical trials, Aimovig has consistently shown to be effective in preventing migraine and bringing relief from the grip of

More from news
Approximately 21 fully matching, plus 125 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,

  • Deal Watch January 2018

    Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine.  In exchange for the licence, Alder will withdraw its appeal

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The cultural construction of illness The cultural construction of illness

    Some years ago, we were asked to advise on marketing a cure for migraines in the UK. ... In this world, migraines were associated with ideas of the overly sensitive, or even hysterical woman, requiring rational male intervention to bring her back to her

  • Ditch the data? Ditch the data?

    Around one in seven people suffer from migraines, and these can impact severely on quality-of-life. ... When a migraine hits, she needs to shut herself in a dark room in silence.

More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Quick links

Infographics

Multimedia